• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is CRISPR Therapeutics (CRSP) Using J.P. Morgan Spotlight to Recast Its Gene-Editing Leadership Story?

    Simply Wall St·01/08/2026 21:31:03
    Listen to the news
    • CRISPR Therapeutics announced that its senior management team would present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, with the presentation webcast live and archived on the company’s website.
    • This conference appearance offers investors a rare, concentrated window into how CRISPR Therapeutics frames the progress of its gene-editing pipeline and collaborations within its broader business story.
    • We’ll now examine how this upcoming J.P. Morgan Healthcare Conference presentation could shape CRISPR Therapeutics’ investment narrative around gene-editing leadership.

    AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    What Is CRISPR Therapeutics' Investment Narrative?

    To own CRISPR Therapeutics, you really have to believe that its broad gene-editing toolkit, from in vivo cardiovascular programs like CTX310 to off-the-shelf CAR T candidates such as zugo-cel, can ultimately translate scientific promise into a sustainable business, despite ongoing losses and no clear path to near-term profitability. The company’s upcoming J.P. Morgan Healthcare Conference slot fits into this by giving management a high-profile stage to refresh the story around its SyNTase platform, autoimmune push and key partnerships, at a time when the stock has risen recently and analysts are already expecting weaker earnings and revenue ahead. That makes the conference more of a sentiment and visibility event than a fundamental catalyst, with the bigger near-term drivers still tied to clinical readouts and cash burn, and the main risks centered on execution, safety and financing.

    CRISPR Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

    Exploring Other Perspectives

    CRSP 1-Year Stock Price Chart
    CRSP 1-Year Stock Price Chart

    Eighteen fair value estimates from the Simply Wall St Community span roughly US$15 to just under US$195, underlining how differently people are thinking about CRISPR Therapeutics’ long-term potential. When you set that against a business that remains unprofitable and heavily reliant on successful trial outcomes, it is easy to see why opinions are so far apart and why it helps to compare several viewpoints before deciding how this stock might fit into a portfolio.

    Explore 18 other fair value estimates on CRISPR Therapeutics - why the stock might be worth over 3x more than the current price!

    Build Your Own CRISPR Therapeutics Narrative

    Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

    Searching For A Fresh Perspective?

    Opportunities like this don't last. These are today's most promising picks. Check them out now:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.